{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T12:57:03Z","timestamp":1696251423993},"reference-count":25,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2007,10,1]],"date-time":"2007-10-01T00:00:00Z","timestamp":1191196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Drug Policy"],"published-print":{"date-parts":[[2007,10]]},"DOI":"10.1016\/j.drugpo.2007.01.007","type":"journal-article","created":{"date-parts":[[2007,2,22]],"date-time":"2007-02-22T14:42:01Z","timestamp":1172155321000},"page":"447-451","source":"Crossref","is-referenced-by-count":16,"title":["Recruitment and follow-up of injecting drug users in the setting of early hepatitis C treatment: Insights from the ATAHC study"],"prefix":"10.1016","volume":"18","author":[{"given":"Oanh K.","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory J.","family":"Dore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John M.","family":"Kaldor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret E.","family":"Hellard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.drugpo.2007.01.007_bib1","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1086\/425361","article-title":"Infrequent reinfection after successful treatment for hepatitis C virus infection in injection drug users","volume":"39","author":"Backmund","year":"2004","journal-title":"Clinical Infectious Diseases"},{"key":"10.1016\/j.drugpo.2007.01.007_bib2","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1053\/jhep.2001.25882","article-title":"Treatment of hepatitis C infection in injection drug users","volume":"34","author":"Backmund","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.drugpo.2007.01.007_bib3","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1477-7517-3-31","article-title":"Therapeutic challenges in hepatitis C-infected drug using patients","volume":"3","author":"Cooper","year":"2006","journal-title":"Harm Reduction Journal"},{"key":"10.1016\/j.drugpo.2007.01.007_bib4","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1136\/jech.51.6.692","article-title":"Epidemiology of hepatitis C virus infection among injecting drug users in Australia","volume":"51","author":"Crofts","year":"1997","journal-title":"Journal of Epidemiology and Community Health"},{"key":"10.1016\/j.drugpo.2007.01.007_bib5","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1056\/NEJM200107193450312","article-title":"Treatment of chronic hepatitis C in active drug users","volume":"345","author":"Davis","year":"2001","journal-title":"New England Journal of Medicine"},{"issue":"Suppl. 5","key":"10.1016\/j.drugpo.2007.01.007_bib6","doi-asserted-by":"crossref","first-page":"S313","DOI":"10.1086\/427446","article-title":"Knowledge and attitudes about treatment for hepatitis C virus infection and barriers to treatment among current injection drug users in Australia","volume":"40","author":"Doab","year":"2005","journal-title":"Clinical Infectious Diseases"},{"key":"10.1016\/j.drugpo.2007.01.007_bib7","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S1386-6532(02)00116-6","article-title":"Epidemiology of hepatitis C virus infection in Australia","volume":"26","author":"Dore","year":"2003","journal-title":"Journal of Clinical Virology"},{"key":"10.1016\/j.drugpo.2007.01.007_bib8","doi-asserted-by":"crossref","first-page":"S210","DOI":"10.1002\/hep.1840360727","article-title":"Prevention and treatment of hepatitis C in injection drug users","volume":"36","author":"Edlin","year":"2002","journal-title":"Hepatology"},{"issue":"Suppl. 5","key":"10.1016\/j.drugpo.2007.01.007_bib9","doi-asserted-by":"crossref","first-page":"S276","DOI":"10.1086\/427441","article-title":"Overcoming barriers to prevention, care, and treatment of hepatitis C in illicit drug users","volume":"40","author":"Edlin","year":"2005","journal-title":"Clinical Infectious Diseases"},{"key":"10.1016\/j.drugpo.2007.01.007_bib10","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1093\/jurban\/jth128","article-title":"Injection drug use and the hepatitis C virus: Considerations for a targeted treatment approach\u2014the case study of Canada","volume":"81","author":"Fischer","year":"2004","journal-title":"Journal of Urban Health"},{"key":"10.1016\/j.drugpo.2007.01.007_bib11","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection","volume":"347","author":"Fried","year":"2002","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.drugpo.2007.01.007_bib12","doi-asserted-by":"crossref","first-page":"346","DOI":"10.7326\/0003-4819-140-5-200403020-00010","article-title":"Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose","volume":"140","author":"Hadziyannis","year":"2004","journal-title":"Annals of Internal Medicine"},{"key":"10.1016\/j.drugpo.2007.01.007_bib13","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1056\/NEJMoa011232","article-title":"Treatment of acute hepatitis C with interferon alfa-2b","volume":"345","author":"Jaeckel","year":"2001","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.drugpo.2007.01.007_bib14","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1053\/j.gastro.2006.01.034","article-title":"Peginterferon alfa-2b therapy in acute hepatitis C: Impact of onset of therapy on sustained virologic response","volume":"130","author":"Kamal","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.drugpo.2007.01.007_bib15","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1002\/hep.20266","article-title":"Pegylated interferon alpha therapy in acute hepatitis C: Relation to hepatitis C virus-specific T cell response kinetics","volume":"39","author":"Kamal","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.drugpo.2007.01.007_bib16","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":"Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial [comment]","volume":"358","author":"Manns","year":"2001","journal-title":"The Lancet"},{"issue":"Suppl. 5","key":"10.1016\/j.drugpo.2007.01.007_bib17","doi-asserted-by":"crossref","first-page":"S325","DOI":"10.1086\/427448","article-title":"Treatment for hepatitis C virus infection among current injection drug users in Australia","volume":"40","author":"Matthews","year":"2005","journal-title":"Clinical Infectious Diseases"},{"key":"10.1016\/j.drugpo.2007.01.007_bib18","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1001\/jama.280.6.567","article-title":"Adherence and antiretroviral therapy in injection drug users","volume":"280","author":"Sherer","year":"1998","journal-title":"Journal of the American Medical Association"},{"key":"10.1016\/j.drugpo.2007.01.007_bib19","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0376-8716(00)00144-7","article-title":"Hepatitis C disease among injection drug users: knowledge, perceived risk and willingness to receive treatment","volume":"61","author":"Stein","year":"2001","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.drugpo.2007.01.007_bib20","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.drugalcdep.2004.07.002","article-title":"The impact of injecting drug use status on hepatitis C-related referral and treatment","volume":"77","author":"Stoove","year":"2005","journal-title":"Drug and Alcohol Dependence"},{"issue":"Suppl. 5","key":"10.1016\/j.drugpo.2007.01.007_bib21","doi-asserted-by":"crossref","first-page":"S304","DOI":"10.1086\/427445","article-title":"Factors associated with interest in initiating treatment for hepatitis C virus (HCV) infection among young HCV-infected injection drug users","volume":"40","author":"Strathdee","year":"2005","journal-title":"Clinical Infectious Diseases"},{"issue":"Suppl. 1","key":"10.1016\/j.drugpo.2007.01.007_bib22","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1086\/429501","article-title":"Approaching treatment for hepatitis C virus infection in substance users","volume":"41","author":"Sylvestre","year":"2005","journal-title":"Clinical Infectious Diseases"},{"key":"10.1016\/j.drugpo.2007.01.007_bib23","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1016\/S0002-9270(03)00708-1","article-title":"Response to treatment of hepatitis C in individuals with a recent history of intravenous drug abuse","volume":"98","author":"Van Thiel","year":"2003","journal-title":"American Journal of Gastroenterology"},{"key":"10.1016\/j.drugpo.2007.01.007_bib24","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/hep.21043","article-title":"Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: The HEP-NET acute-HCV-II study","volume":"43","author":"Wiegand","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.drugpo.2007.01.007_bib25","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1002\/hep.20132","article-title":"Hepatitis C virus-infected patients report communication problems with physicians","volume":"39","author":"Zickmund","year":"2004","journal-title":"Hepatology"}],"container-title":["International Journal of Drug Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0955395907000084?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0955395907000084?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,9]],"date-time":"2019-01-09T04:59:48Z","timestamp":1547009988000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0955395907000084"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,10]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2007,10]]}},"alternative-id":["S0955395907000084"],"URL":"https:\/\/doi.org\/10.1016\/j.drugpo.2007.01.007","relation":{},"ISSN":["0955-3959"],"issn-type":[{"value":"0955-3959","type":"print"}],"subject":[],"published":{"date-parts":[[2007,10]]}}}